COVID-19 UPDATE

BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

Analyst Coverage

Analyst Coverage

Analyst
Firm
Brandon Folkes
Cantor Fitzgerald
Oren Livnat
HC Wainwright & Co.
Tim Chiang
Northland Securities
David Amsellem
Piper Sandler
Scott Henry
ROTH Capital Partners
Gregg Gilbert
SunTrust Robinson Humphrey, Inc.
Tim Lugo
William Blair

BioDelivery Sciences International, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding BioDelivery Sciences International, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of BioDelivery Sciences International, Inc. or its management. BioDelivery Sciences International, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Investor Presentation

More information is coming soon.


Recent BDSI News

BioDelivery Sciences Expects 2021 Revenue at the High End of Full Year Guidance January 20, 2022

Total 2021 Net Revenue expected in the range of $165 - $167 million , as compared to previous guidance of $162-$167 million BELBUCA 2021 Net Sales expected to be in the range of $147 - $148 million , as compared to previous guidance of $144-$148 million 2021 EBITDA expected to be in the $40 - $45 ...

Read more
BioDelivery Sciences Prevails in BELBUCA® ANDA Litigation Maintaining Patent Exclusivity Against Alvogen Until 2032 December 20, 2021

RALEIGH, N.C. , Dec. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that the U.S. ...

Read more
BioDelivery Sciences Reports Solid Third Quarter 2021 Results November 3, 2021

Total Net Revenue of $41.1 Million , an Increase of 4% versus Prior Year Strong profitability with GAAP EPS of $0.07 , EBITDA Margin of 27% and $7.0 million Operating Cash Flow Closed acquisition of ELYXYB, the first FDA-approved, ready-to-use oral solution for acute migraine with potential ...

Read more

Upcoming Events

More events are coming soon.

Stay Connected

Stay up to date on the latest news

Get started now
November 3, 2021 /
Data provided by West LLC. Minimum 15 minutes delayed.